Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50%

MLA

Giovanni Mansueto, et al. Clinicopathologic Correlates of First-Line Pembrolizumab Effectiveness in Patients with Advanced NSCLC and a PD-L1 Expression of ≥ 50%. Jan. 2020. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....299351854891d785717f66ecb3cc59b1&authtype=sso&custid=ns315887.

APA

Giovanni Mansueto, Lorenza Landi, Francesco Grossi, Cinzia Baldessari, Michele De Tursi, Alessio Cortellini, Vincenzo Sforza, Alain Gelibter, Raffaele Giusti, Biagio Ricciuti, Giuseppe Luigi Banna, Daniele Santini, Giorgia Guaitoli, Joachim G.J.V. Aerts, Russano Marco, Rita Chiari, Ornella Cantale, Luca Sala, Mariangela Torniai, … Alessio Grieco. (2020). Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50%.

Chicago

Giovanni Mansueto, Lorenza Landi, Francesco Grossi, Cinzia Baldessari, Michele De Tursi, Alessio Cortellini, Vincenzo Sforza, et al. 2020. “Clinicopathologic Correlates of First-Line Pembrolizumab Effectiveness in Patients with Advanced NSCLC and a PD-L1 Expression of ≥ 50%,” January. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....299351854891d785717f66ecb3cc59b1&authtype=sso&custid=ns315887.